Firm
The firm reported a small uptick in overall revenue and profit per equity partner, while its IP team secured notable life sciences victories
Paul Ainsworth, who secured a settlement for his client in a patent dispute, says the case shows why medical claims by dietary supplement companies can threaten IP rights
Boies Schiller Flexner joins forces with Grünecker to target Skechers in Europe following US lawsuit
Helen Mutimer discusses how the firm’s IP advisory services are filling a gap in the market, and why life sciences work is soaring
Sponsored
Sponsored
-
Sponsored by Bird & BirdMax Walters joins Sally Shorthose and James Baillieu of Bird & Bird and Henry Hadad of Bristol Myers Squibb to discuss how COVID-19 has shaped transactional work -
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer of Maiwald explores a recent decision which prevents the distribution of medicinal products by means of an automatic dispenser from a foreign mail-order pharmacy
-
Sponsored by Liu, Shen & AssociatesXiaoming Zhang of Liu Shen & Associates takes a closer look at the Draft for Comments to the Patent Examination Guidelines and discusses its positive approach towards AI-related applications
-
Sponsored by Vivien Chan & CoExperts from Vivien Chan & Co report on significant developments from the IP world across China and the Asia-Pacific
-
Sponsored by Griffith HackKaren Sinclair and Sarah Cox of Griffith Hack review the Australian federal government’s budget measures for R&D, innovation, and medical technology funding
